What are the characteristics of PHARMING GROUP stock?

PHARMING GROUP is a company operating in the Biotechnologies sector. The stock is listed on Euronext Amsterdam under ISIN NL0010391025.

What is the recent price evolution of PHARMING GROUP stock?

Since last close: 10.91 %. Over one week: 9.67 %. Over one year: -19.02 %.

Pharming Group to Participate in the Jefferies Global Healthcare Conference in New York

CEO Fabrice Chouraqui will engage in a Fireside Chat session on Thursday, June 4.

Published on Jun 02, 2026 at 10:09

PHARMING GROUP

0.94 € +10.91 %

Add us as a preferred source on Google

A presentation for investors and sector analysts

Pharming Group is participating in the Jefferies Global Healthcare Conference held in New York on June 3 and 4, 2026. Fabrice Chouraqui, CEO of the group, will take part in a question-and-answer session (Fireside Chat) on Thursday, June 4 at 11:05 AM Eastern Time / 5:05 PM Paris Time. This participation is part of Pharming's regular interactions with investors and health sector analysts. The presentation will be broadcast live, and a replay will be available in the 'Events and Presentations' and 'News' sections of Pharming's website.

Free · Every morning

Technical market signals, before the opening bell.

Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.

✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis

Indicative data. No investment advice. Unsubscribe at any time.

🏢 Other stocks — Santé

🗞️ UCB share price breaks through €219 and surges nearly 12% following raised targets 🗞️ Nanobiotix share declines 1% but posts +22% on the week 🗞️ Abivax stock drops 30% over the quarter and turns red again 🗞️ Valneva stock breaks below its €2.42 support level and continues to decline

Context

Period

Period: T3 2026

Key reported figures

Revenue: 117,6 millions de dollars
Quarterly revenue: 117,6 millions de dollars
Revenue growth: 21 %

Guidance from the release

Tightened 2026 total revenue guidance to between US$380 million and US$390 million from prior US$375 million to US$395 million

Risks mentioned

Joenja revenue growth was partly driven by temporary benefit from ordering patterns in other international markets
RUCONEST third quarter revenue includes an early seasonal increase in channel inventory at a single U.S. specialty pharmacy customer, following significant drawdowns earlier in the year
Napazimone (KL1333): enrollment in the pivotal FALCON trial now expected to complete in the first half of 2027 (about 145 of 180 subjects by end-2026), with topline results approximately one year after completion of enrollment

Opportunities identified

RUCONEST stabilization and continued recovery of demand in the US (third quarter revenue of about US$93.8 million, +14% year-on-year and +30% versus the second quarter of 2026)
Joenja strong growth driven by launches in Germany, Japan and continued penetration in the U.K.
Substantial growth potential for Joenja with estimated CVID with immune dysregulation prevalence of 39 patients per million vs 1.5 for APDS

Outlook / guidance

Expected revenue: 385 millions de dollars
Management commentary: Tightened 2026 total revenue guidance to between US$380 million and US$390 million (1% to 4% growth) from prior US$375 million to US$395 million (0% to 5% growth)

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

A presentation for investors and sector analysts

Context

Also read